Kymera Total Stockholder Equity vs Short Term Debt Analysis

KYMR Stock

USD 46.85 0.01 0.02%

Kymera Therapeutics financial indicator trend analysis is infinitely more than just investigating Kymera Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kymera Therapeutics is a good investment. Please check the relationship between Kymera Therapeutics Total Stockholder Equity and its Short Term Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.

Total Stockholder Equity vs Short Term Debt

Total Stockholder Equity vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kymera Therapeutics Total Stockholder Equity account and Short Term Debt. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Kymera Therapeutics' Total Stockholder Equity and Short Term Debt is 0.9. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Kymera Therapeutics, assuming nothing else is changed. The correlation between historical values of Kymera Therapeutics' Total Stockholder Equity and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Kymera Therapeutics are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Total Stockholder Equity i.e., Kymera Therapeutics' Total Stockholder Equity and Short Term Debt go up and down completely randomly.

Correlation Coefficient

0.9

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Short Term Debt

Most indicators from Kymera Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kymera Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.At this time, Kymera Therapeutics' Sales General And Administrative To Revenue is relatively stable compared to the past year. As of 11/29/2024, Enterprise Value is likely to grow to about 1.9 B, while Selling General Administrative is likely to drop slightly above 30.3 M.

	2021	2022	2023	2024 (projected)
Interest Expense	175K	176K	196K	132.7K
Depreciation And Amortization	2.4M	3.0M	3.6M	2.3M

Interest Expense Depreciation And Amortization

Kymera Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.66	0.94	0.94	0.99	0.81	0.95	0.57	0.79	0.5	-0.84	0.88	0.54	0.74	-0.57	0.89	0.98	0.55	0.78	-0.2	0.66	0.96	0.96	0.72	0.99	0.67
Short Long Term Debt Total	0.66		0.74	0.64	0.6	0.54	0.8	0.99	0.38	0.47	-0.91	0.86	0.8	0.84	0.06	0.84	0.55	0.97	0.72	0.13	1.0	0.73	0.68	0.69	0.6	1.0
Other Current Liab	0.94	0.74		0.81	0.94	0.61	0.94	0.68	0.54	0.31	-0.92	0.92	0.76	0.65	-0.56	0.95	0.88	0.66	0.92	-0.15	0.74	0.99	0.97	0.63	0.94	0.76
Total Current Liabilities	0.94	0.64	0.81		0.89	0.94	0.87	0.55	0.91	0.65	-0.72	0.85	0.43	0.82	-0.38	0.76	0.93	0.5	0.65	-0.02	0.64	0.85	0.83	0.86	0.89	0.64
Total Stockholder Equity	0.99	0.6	0.94	0.89		0.72	0.95	0.52	0.74	0.46	-0.83	0.83	0.49	0.66	-0.65	0.88	0.98	0.51	0.76	-0.35	0.6	0.97	0.98	0.59	1.0	0.62
Other Liab	0.81	0.54	0.61	0.94	0.72		0.7	0.44	0.96	0.64	-0.56	0.74	0.29	0.83	-0.2	0.56	0.82	0.38	0.47	0.18	0.54	0.66	0.64	0.91	0.72	0.52
Net Tangible Assets	0.95	0.8	0.94	0.87	0.95	0.7		0.74	0.68	0.53	-0.94	0.89	0.6	0.79	-0.46	0.96	0.92	0.74	0.79	-0.28	0.8	0.96	0.96	0.64	0.95	0.82
Property Plant And Equipment Net	0.57	0.99	0.68	0.55	0.52	0.44	0.74		0.28	0.43	-0.88	0.8	0.79	0.79	0.14	0.8	0.46	0.99	0.68	0.14	0.99	0.66	0.61	0.62	0.52	0.99
Current Deferred Revenue	0.79	0.38	0.54	0.91	0.74	0.96	0.68	0.28		0.69	-0.46	0.61	0.07	0.74	-0.31	0.5	0.84	0.25	0.34	-0.06	0.38	0.62	0.63	0.76	0.74	0.37
Net Debt	0.5	0.47	0.31	0.65	0.46	0.64	0.53	0.43	0.69		-0.38	0.51	0.0	0.78	0.23	0.32	0.47	0.47	0.01	-0.18	0.47	0.42	0.44	0.49	0.46	0.46
Retained Earnings	-0.84	-0.91	-0.92	-0.72	-0.83	-0.56	-0.94	-0.88	-0.46	-0.38		-0.9	-0.79	-0.77	0.32	-0.97	-0.76	-0.88	-0.85	0.13	-0.91	-0.91	-0.89	-0.61	-0.83	-0.93
Accounts Payable	0.88	0.86	0.92	0.85	0.83	0.74	0.89	0.8	0.61	0.51	-0.9		0.8	0.85	-0.22	0.86	0.79	0.78	0.82	0.11	0.86	0.92	0.89	0.81	0.83	0.86
Cash	0.54	0.8	0.76	0.43	0.49	0.29	0.6	0.79	0.07	0.0	-0.79	0.8		0.5	-0.11	0.74	0.4	0.75	0.87	0.34	0.8	0.69	0.61	0.57	0.49	0.8
Non Current Assets Total	0.74	0.84	0.65	0.82	0.66	0.83	0.79	0.79	0.74	0.78	-0.77	0.85	0.5		0.11	0.68	0.68	0.78	0.47	0.12	0.84	0.69	0.68	0.82	0.66	0.82
Non Currrent Assets Other	-0.57	0.06	-0.56	-0.38	-0.65	-0.2	-0.46	0.14	-0.31	0.23	0.32	-0.22	-0.11	0.11		-0.48	-0.65	0.15	-0.54	0.5	0.06	-0.55	-0.58	-0.04	-0.65	0.02
Other Assets	0.89	0.84	0.95	0.76	0.88	0.56	0.96	0.8	0.5	0.32	-0.97	0.86	0.74	0.68	-0.48		0.83	0.78	0.9	-0.2	0.84	0.94	0.91	0.6	0.88	0.86
Cash And Short Term Investments	0.98	0.55	0.88	0.93	0.98	0.82	0.92	0.46	0.84	0.47	-0.76	0.79	0.4	0.68	-0.65	0.83		0.43	0.72	-0.27	0.55	0.91	0.92	0.68	0.98	0.57
Net Receivables	0.55	0.97	0.66	0.5	0.51	0.38	0.74	0.99	0.25	0.47	-0.88	0.78	0.75	0.78	0.15	0.78	0.43		0.61	0.04	0.97	0.65	0.61	0.53	0.51	0.98
Common Stock Shares Outstanding	0.78	0.72	0.92	0.65	0.76	0.47	0.79	0.68	0.34	0.01	-0.85	0.82	0.87	0.47	-0.54	0.9	0.72	0.61		0.07	0.72	0.86	0.8	0.62	0.76	0.73
Non Current Liabilities Total	-0.2	0.13	-0.15	-0.02	-0.35	0.18	-0.28	0.14	-0.06	-0.18	0.13	0.11	0.34	0.12	0.5	-0.2	-0.27	0.04	0.07		0.13	-0.22	-0.31	0.48	-0.35	0.08
Capital Lease Obligations	0.66	1.0	0.74	0.64	0.6	0.54	0.8	0.99	0.38	0.47	-0.91	0.86	0.8	0.84	0.06	0.84	0.55	0.97	0.72	0.13		0.73	0.68	0.69	0.6	1.0
Other Current Assets	0.96	0.73	0.99	0.85	0.97	0.66	0.96	0.66	0.62	0.42	-0.91	0.92	0.69	0.69	-0.55	0.94	0.91	0.65	0.86	-0.22	0.73		0.99	0.63	0.97	0.75
Other Stockholder Equity	0.96	0.68	0.97	0.83	0.98	0.64	0.96	0.61	0.63	0.44	-0.89	0.89	0.61	0.68	-0.58	0.91	0.92	0.61	0.8	-0.31	0.68	0.99		0.56	0.98	0.7
Total Liab	0.72	0.69	0.63	0.86	0.59	0.91	0.64	0.62	0.76	0.49	-0.61	0.81	0.57	0.82	-0.04	0.6	0.68	0.53	0.62	0.48	0.69	0.63	0.56		0.59	0.66
Net Invested Capital	0.99	0.6	0.94	0.89	1.0	0.72	0.95	0.52	0.74	0.46	-0.83	0.83	0.49	0.66	-0.65	0.88	0.98	0.51	0.76	-0.35	0.6	0.97	0.98	0.59		0.62
Property Plant And Equipment Gross	0.67	1.0	0.76	0.64	0.62	0.52	0.82	0.99	0.37	0.46	-0.93	0.86	0.8	0.82	0.02	0.86	0.57	0.98	0.73	0.08	1.0	0.75	0.7	0.66	0.62

Click cells to compare fundamentals

Kymera Therapeutics Account Relationship Matchups

Kymera Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	116.7M	487.2M	605.9M	603.1M	575.8M	446.0M
Short Long Term Debt Total	21.2M	18.0M	18.0M	17.3M	84.7M	88.9M
Other Current Liab	4.6M	7.2M	19.6M	23.9M	28.0M	15.3M
Total Current Liabilities	34.6M	110.6M	101.0M	63.3M	85.7M	73.3M
Total Stockholder Equity	(74.4M)	283.9M	459.6M	490.2M	395.0M	278.6M
Other Liab	29.6M	77.9M	39.4M	28.2M	32.5M	38.6M
Net Tangible Assets	(74.4M)	283.9M	459.6M	490.2M	563.7M	591.9M
Property Plant And Equipment Net	22.1M	10.8M	11.9M	13.3M	101.1M	106.1M
Current Deferred Revenue	23.3M	170.4M	101.0M	63.3M	37.9M	73.0M
Net Debt	(54.8M)	(13.0M)	(30.0M)	(51.1M)	(25.3M)	(26.6M)
Retained Earnings	(76.5M)	(128.8M)	(229.0M)	(383.8M)	(530.8M)	(504.2M)
Accounts Payable	3.3M	4.4M	4.0M	4.3M	7.1M	4.6M
Cash	76.0M	31.0M	48.0M	68.4M	110.0M	68.7M
Non Current Assets Total	23.9M	184.8M	38.3M	43.6M	170.4M	179.0M
Non Currrent Assets Other	1.8M	11.5M	(98.8M)	(122.0M)	7.9M	8.3M
Other Assets	1.8M	1.6M	8.1M	9.1M	10.5M	11.0M
Cash And Short Term Investments	92.0M	458.7M	567.6M	559.5M	374.9M	383.9M
Net Receivables	287K	1.4M	135K	2.5M	18.8M	19.7M
Common Stock Shares Outstanding	44.5M	17.3M	48.0M	53.9M	58.4M	44.4M
Short Term Investments	15.9M	265.2M	394.4M	338.8M	264.9M	234.5M
Liabilities And Stockholders Equity	116.7M	487.2M	605.9M	603.1M	575.8M	446.0M
Non Current Liabilities Total	156.5M	92.7M	45.2M	49.7M	95.1M	68.4M
Capital Lease Obligations	21.2M	18.0M	18.0M	17.3M	84.7M	88.9M
Other Current Assets	888K	4.7M	8.7M	9.7M	11.7M	6.6M
Other Stockholder Equity	(107.0M)	412.8M	689.3M	878.9M	926.3M	513.5M
Total Liab	191.1M	203.3M	146.3M	113.0M	180.8M	167.4M
Net Invested Capital	(74.4M)	283.9M	459.6M	490.2M	395.0M	278.6M
Property Plant And Equipment Gross	22.1M	20.7M	25.2M	29.1M	111.5M	117.1M
Total Current Assets	92.8M	302.3M	567.6M	559.5M	405.3M	361.1M
Accumulated Other Comprehensive Income	6K	(128K)	(660K)	(4.9M)	(552K)	(579.6K)
Net Working Capital	58.3M	191.7M	358.7M	348.1M	319.6M	240.8M
Short Term Debt	3.4M	6.5M	7.2M	7.9M	12.7M	7.0M
Property Plant Equipment	22.1M	20.7M	11.9M	13.3M	15.3M	15.4M

Pair Trading with Kymera Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.

The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Kymera Stock Analysis

When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kymera Total Stockholder Equity vs Short Term Debt Analysis

Total Stockholder Equity vs Short Term Debt

Total Stockholder Equity vs Short Term Debt Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Short Term Debt

Kymera Therapeutics fundamental ratios Correlations

Kymera Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kymera Therapeutics fundamental ratios Accounts

Pair Trading with Kymera Therapeutics

Additional Tools for Kymera Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Capital Lease Obligations
Total Stockholder Equity	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Total Assets

Other Assets	- 0.97	Retained Earnings
Retained Earnings	- 0.94	Net Tangible Assets
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Retained Earnings	- 0.92	Other Current Liab
Other Current Assets	- 0.91	Retained Earnings
Capital Lease Obligations	- 0.91	Retained Earnings